- Global Pharma News & Resources

Annual General Meeting of Zur Rose Group AG: Shareholders approve all proposals

EQS Group-News: Zur Rose Group AG / Key word(s): AGMEGM
29.04.2021 / 18:00

Frauenfeld, 29 April 2021
Press release

2021 Annual General Meeting of Zur Rose Group AG

Shareholders approve all proposals

The 28th Annual General Meeting of Zur Rose Group AG took place today in Zurich. Due to the ongoing extraordinary situation in connection with the corona pandemic, the meeting was again held without the personal participation of the shareholders. The shareholders of Zur Rose Group AG were able to exercise their rights at the Annual General Meeting exclusively through the independent proxy. In total, 5,198,863 shareholder votes, equivalent to 49.38 per cent of the share capital or 77.05 per cent of the shares entitled to vote, were represented by the independent proxy. The Board of Directors would like to thank all those who exercised their shareholder rights in this way.

The shareholders approved the Management Report, the Annual Financial Statements and Consolidated Financial Statements for 2020 and the appropriation of retained earnings and ratified the actions taken by the Board of Directors and Group Management during the year. The Chairman of the Board of Directors and the members of the Board of Directors standing for re-election as well as all members of the Compensation Committee were confirmed for a further term of office of one year. Prof. Dr. Andréa Belliger was newly elected to the Board of Directors. Further, the Annual General Meeting approved the proposed maximum total amounts of compensation for the members of the Board of Directors and the Group Management. In addition, the compensation report for the 2020 financial year was approved in a consultative vote. Ernst & Young AG as auditors and Fürer Partner Advocaten KIG as independent proxy were confirmed for a further term of office of one year.

Furthermore, the shareholders approved the proposal to create authorized share capital in the nominal amount of CHF 31,579,080, corresponding to 10 per cent of the registered share capital, and to increase the conditional share capital for financing, acquisitions and other purposes to CHF 31,579,080. At the same time, the shareholders resolved to include a provision in the Articles of Association pursuant to which the total number of shares that may be issued from authorized and conditional share capital is limited to a total of 10 per cent of the current registered share capital (corresponding to 1,052,636 registered shares).

Likewise, the shareholders resolved an amendment to the Articles of Association granting the Board of Directors flexibility with respect to the designation of the Compensation Committee.

The minutes with the detailed voting results will be available at " > Investors & Media > Annual General Meeting" as of 30 April 2021.

Investors and analyst contact
Christoph Herrmann, Head of Investor Relations
Email:, phone: +41 58 810 11 49

Media contact
Lisa Lüthi, Head of Group Communications
Email:, phone: +41 52 724 08 14

A Capital Markets Day in virtual format will take place on 16 June 2021. Invitation and agenda will follow at a later date.

18 August 2021 Half-Year Results
21 October 2021 Q3 Trading Update

Zur Rose Group

The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. It also operates the leading marketplace in southern Europe for consumer health, beauty and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany's best-known pharmacy brand, DocMorris, and employs more than 2,200 people at sites in Switzerland, Germany, the Netherlands, Spain and France. Now serving more than 11 million active customers in core European markets, Zur Rose generated revenue of CHF 1,752 million (including external revenue) in 2020.

With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care. It also excels in continuous development of digital healthcare services and as a platform technology provider. In addition, Zur Rose is actively driving forward its positioning as a comprehensive healthcare service provider, with focus on building up its European healthcare ecosystem networking qualified providers of products, services and digital solutions. Zur Rose's contribution will be to bring these offerings to customers and patients, pursuing its vision of creating a world where people can manage their own health in one click.

The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information, please visit

End of Media Release

Language: English
Company: Zur Rose Group AG
Walzmühlestrasse 60
8500 Frauenfeld
Phone: +41 52 724 08 14
ISIN: CH0042615283
Listed: SIX Swiss Exchange
EQS News ID: 1190829

End of News EQS Group News Service

Editor Details

Last Updated: 29-Apr-2021